Literature DB >> 11979382

Ultrasonographically assessed carotid atherosclerosis in Japanese type 2 diabetic patients: Role of nonesterified fatty acids.

Ataru Taniguchi1, Yoshikatsu Nakai, Mitsuo Fukushima, Satoshi Teramura, Ryuji Hayashi, Kenichi Hama, Keiichi Marumoto, Toshiki Watanabe, Ikuko Yoshioka, Kenji Sakaguchi, Hiroyuki Kishimoto, Katsuyo Matsushita, Takahide Okumura, Kumpei Tokuyama, Shoichiro Nagasaka, Masahiko Sakai.   

Abstract

The aim of the present study was to evaluate the association of carotid atherosclerosis (intimal-medial thickness [IMT] in plaque-free segments and carotid stenosis in plaque segments) with serum nonesterified fatty acids (NEFA) in diabetic and nondiabetic patients. Fifty-one nonobese nonhypertensive Japanese type 2 diabetic patients aged 38 to 83 years (60.0 +/- 1.5 years, mean +/- SEM) and 23 age-matched (60.4 +/- 2.2 years, P =.439; range, 36 to 74 years) and sex-matched nondiabetic subjects were examined. The duration of diabetes was 9.6 +/- 1.0 years. Body mass index (BMI), blood pressure (systolic pressure, diastolic pressure), glycosylated hemoglobin (HbA(1c)), and fasting concentrations of plasma glucose, serum lipids (triglycerides, total, and high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol) and serum NEFA were measured. Using high-resolution B-mode ultrasound scan, we measured IMT in plaque-free segments of bilateral common carotid arteries, and the mean of IMT in 2 vessels was used for the analysis. Furthermore, we calculated the degree of stenosis in plaque segments of bilateral common carotid arteries. The degree of carotid stenosis was expressed as a percentage ratio between the area of plaque and that of the lumen using the formula (Lumen Area - Residual Lumen) x 100. Both the areas were automatically measured by the system on a frozen transverse scanning plane at the site of maximal narrowing. When 2 or more plaques were present in the vessel, only that causing the greatest degree of stenosis was considered for analysis. Univariate regression analyses showed that mean IMT in plaque-free segments was positively correlated with age (r =.498, P =.0004) and NEFA (r =.354, P =.0188) in type 2 diabetic patients. The degree of stenosis was positively correlated to age (r =.422, P =.0028), duration of diabetes (r =.313, P =.0268) and NEFA (r =.540, P =.0003) in diabetic patients. Other variables, including BMI and lipid profile, were not associated both with mean IMT in plaque-free segments and the degree of stenosis in plaque segments in our diabetic patients. Multiple regression analyses showed that mean IMT in plaque-free segments was independently associated with age (P =.0003, F = 15.2), which explained 26.1% of the variability of IMT in our diabetic patients. The degree of stenosis was independently predicted by NEFA (P =.0047, F = 8.9), which explained 17.2% of the variability of the carotid stenosis in our diabetic patients. In contrast, mean IMT in plaque-free segments was positively correlated to age in nondiabetic subjects (r =.450, P =.0347). There was, however, no relationship between the degree of stenosis and the variables, including age and NEFA, in nondiabetic subjects. These results indicate that the factors contributing to IMT in plaque-free segments and the degree of carotid stenosis in plaque segments are different in nonobese nonhypertensive Japanese type 2 diabetic patients. IMT in plaque-free segments was independently associated with age both in nondiabetic and diabetic subjects, whereas the serum NEFA level independently predicted the degree of stenosis in plaque segments in our diabetic patients, while not in nondiabetic subjects. Thus, NEFA is considered to be one of the new risk factors responsible for the progression of carotid atherosclerosis in nonobese nonhypertensive Japanese type 2 diabetic patients. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979382     DOI: 10.1053/meta.2002.31970

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  Postprandial lipid responses to standard carbohydrates used to determine glycaemic index values.

Authors:  Sonia Vega-López; Lynne M Ausman; Nirupa R Matthan; Alice H Lichtenstein
Journal:  Br J Nutr       Date:  2013-05-09       Impact factor: 3.718

2.  Free fatty acids are associated with insulin resistance but not coronary artery atherosclerosis in rheumatoid arthritis.

Authors:  Michelle J Ormseth; Larry L Swift; Sergio Fazio; Macrae F Linton; Cecilia P Chung; Paolo Raggi; Young Hee Rho; Joseph Solus; Annette Oeser; Aihua Bian; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  Atherosclerosis       Date:  2011-09-12       Impact factor: 5.162

3.  Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus.

Authors:  M J Ormseth; L L Swift; S Fazio; M F Linton; P Raggi; J F Solus; A Oeser; A Bian; T Gebretsadik; A Shintani; C M Stein
Journal:  Lupus       Date:  2012-10-11       Impact factor: 2.911

4.  Impact of free fatty acids on prognosis in coronary artery disease patients under different glucose metabolism status.

Authors:  Jing-Lu Jin; Ye-Xuan Cao; Hui-Hui Liu; Hui-Wen Zhang; Yuan-Lin Guo; Na-Qiong Wu; Cheng-Gang Zhu; Rui-Xia Xu; Ying Gao; Jing Sun; Qian Dong; Jian-Jun Li
Journal:  Cardiovasc Diabetol       Date:  2019-10-14       Impact factor: 9.951

5.  Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes.

Authors:  Sudabeh Alatab; Hossein Fakhrzadeh; Farshad Sharifi; Ali Mostashfi; Mojde Mirarefin; Zohreh Badamchizadeh; Yaser Tagalizadehkhoob
Journal:  J Diabetes Metab Disord       Date:  2014-01-29

6.  Correlation between serum free fatty acids levels and Gensini score in elderly patients with coronary heart disease.

Authors:  Li-Yun He; Jun-Feng Zhao; Jiang-Li Han; Shan-Shan Shen; Xu-Jiao Chen
Journal:  J Geriatr Cardiol       Date:  2014-03       Impact factor: 3.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.